Media

Media Coverage • 26 July 2024

Nectin Therapeutics Licenses Novel Antibodies to Immunome

Media Coverage • 25 July 2024

Immunome bets on Nectin's antibodies for next-gen ADCs

Media Coverage • 6 May 2024

Nectin Therapeutics Secures $10 Million from GIBF to Propel Immunotherapy

Media Coverage • 27 December 2023

Nectin expands Phase I trial of NTX1088 combination to global sites

Media Coverage • 26 December 2023

Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel

Media Coverage • 18 December 2023

Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent

Media Coverage • 18 May 2023

Myeloma Investment Fund invests in Nectin Therapeutics to evaluate multiple myeloma drug candidate

Media Coverage • 16 May 2023

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Media Coverage • 16 February 2023

Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm

Biospace logo
Media Coverage • 7 February 2023

Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda

Media Coverage • 7 February 2023

MSD and Nectin to Collaborate on Clinical Trial for Keytruda® Combination

Media Coverage • 7 February 2023

Nectin Therapeutics to Collaborate with Merck on Clinical Trial of Anti-PVR Antibody in Combination with Keytruda in Patients with Locally Advanced & Metastatic Solid Tumors

Media Coverage • 1 December 2022

Nectin Doses First Subject in Phase I Solid Tumour Immunotherapy Trial

Media Coverage • 1 December 2022

Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors

Media Coverage • 30 November 2022

Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies

Media Coverage • 30 November 2022

MD Anderson VC Arm Joins $25M Funding Round for Cancer Drug Company

Biospace logo
Media Coverage • 30 November 2022

Nectin's Series A Hits $25M as Investors Support New Target for Solid Tumors | BioSpace